CTI’s Pixuvri Flops Again At British NICE, As Discount Fails To Impress
This article was originally published in The Pink Sheet Daily
Executive Summary
Despite a sizeable price cut, uncertainty surrounding CTI’s non-Hodgkin’s lymphoma therapy Pixuvri has landed it with a second NICE rejection.
You may also be interested in...
Cell Therapeutics’ Tosedostat Gets Back On Track
FDA lifts clinical hold on first-in-class aminopeptidase inhibitor tosedostat, in investigator-sponsored Phase II trials for blood-related cancers as part of the company’s economic development strategy.
Cell Therapeutics’ Tosedostat Gets Back On Track
FDA lifts clinical hold on first-in-class aminopeptidase inhibitor tosedostat, in investigator-sponsored Phase II trials for blood-related cancers as part of the company’s economic development strategy.
CTI Finds Pixuvri’s Conditional Authorization Is Not Enough To Win NICE Approval
In an early stage decision, NICE rejects Pixuvri for multiply relapsed or refractory aggressive non-Hodgkin's lymphoma, citing lack of evidence and cost-effectiveness.